Finally, interim results of a phase 2 trial of crenolanib in combination with salvage idarubicin and HDAC in multiply R/R FLT3-mutated AML showed a CRc rate of 67% from a total of six patients who received ≤2 prior AML therapies, while no one with >2 prior treatments achieved CR [73]. This evidence concerns the gene HDAC9 and acute myeloid leukemia.